Oncimmune (LON:ONC) Releases Earnings Results

Oncimmune (LON:ONC) posted its quarterly earnings data on Monday. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter, Digital Look Earnings reports. Oncimmune had a net margin of 586.08% and a negative return on equity of 760.96%.

Oncimmune Price Performance

Shares of Oncimmune stock opened at GBX 8.01 ($0.10) on Wednesday. Oncimmune has a fifty-two week low of GBX 7.50 ($0.09) and a fifty-two week high of GBX 31 ($0.39). The company has a market cap of £5.94 million, a PE ratio of -267.13 and a beta of 1.19. The firm has a fifty day moving average price of GBX 13.37 and a two-hundred day moving average price of GBX 14.80. The company has a debt-to-equity ratio of 806.85, a current ratio of 1.13 and a quick ratio of 0.63.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.